The company is using a trigger for Alzheimer’s disease pathology around which they have developed a patented strategy for correcting the condition. Their research points to plaques and tangles as the effect of a more serious underlying condition which triggers those pathological features. Leucadia’s Arethusta technology is based on the idea of improving cerebrospinal fluid (CSF) clearance of metabolites from intercellular spaces in the brain. Aging and events during life can occlude the cribiform plate, a porous bone where CSF drains across, and reduce CSF-mediated clearance of toxic metabolites. Arethusta restores CSF flow across the cribiform plate.
The name of the treatment device, Arethusa, is based on the water nymph from Greek mythology who was saved by Artemis by turning her into a hidden underground stream. By analogy, Leucadia’s device will create an under-the-tissue channel to drain fluid from the brain. The Arethusta device will be introduced through the nose as the cribriform plate is at the top of the nasal cavity.
Founding investors include the Methuselah Foundation and the Methuselah Fund.
On December 8, 2017 Leucadia Therapeutics completed their seed funding round with an undisclosed amount of funding from the Methuselah Foundation.
Leucadia Therapeutics was founded.
Undoing Aging: Doug Ethell's Presentation on the Leucadia Therapeutics Approach to Treating Alzheimer's Disease
What If Alzheimer's Disease Is Caused by "Bad Plumbing"?
Documentaries, videos and podcasts
- Alzheimer's diseaseChronic neurodegenerative disease that usually starts slowly and worsens over time. it is the cause of 60% to 70% of cases of dementia
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.